Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial

Bristol Myers Squibb & Co BMY has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC).
The trial evaluated Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as neoadjuvant treatment.
The study met the primary endpoint of improved event-free survival (EFS). Opdivo/Chemo combo showed a statistically significant and clinically meaningful improvement in EFS compared to chemotherapy alone.
This combination previously showed a significant improvement of pathologic complete response (pCR), the trial's other primary endpoint.
The Company will complete a full evaluation of the available CheckMate -816 data and share the results at an upcoming medical conference.
Price Action: BMY shares are up 0.60% at $59.80 during the market session on the last check Monday.

Momentum54.90

Growth70.29

QualityNot Available

Value29.75

Short

Medium

Long